PE20220173A1 - Composiciones farmaceuticas inyectables y usos de las mismas - Google Patents

Composiciones farmaceuticas inyectables y usos de las mismas

Info

Publication number
PE20220173A1
PE20220173A1 PE2021001827A PE2021001827A PE20220173A1 PE 20220173 A1 PE20220173 A1 PE 20220173A1 PE 2021001827 A PE2021001827 A PE 2021001827A PE 2021001827 A PE2021001827 A PE 2021001827A PE 20220173 A1 PE20220173 A1 PE 20220173A1
Authority
PE
Peru
Prior art keywords
radicals
membered
injectable pharmaceutical
halogen
optionally substituted
Prior art date
Application number
PE2021001827A
Other languages
English (en)
Inventor
Colon Brenda L Valle
Keith Freehauf
Frank Guerino
Christopher D Kulczar
Brian Carrillo
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of PE20220173A1 publication Critical patent/PE20220173A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Una composicion farmaceutica inyectable que comprende particulas de un compuesto de isoxazolina de formula (I), en donde R1 es halogeno, CF3, OCF3, CN; n es de 0 a 3; R2 es haloalquilo C1-C3; T es un sistema de anillo mono o biciclico de 5 a 12 miembros, que esta opcionalmente sustituido por uno o mas radicales Y; Y es metilo, halometilo, halogeno, CN, NO2, NH2-C=S, o dos radicales adyacentes Y forman juntos una cadena de tres o cuatro miembros; Q es X-NR3R4 o un anillo N-heteroarilo de 5 miembros, que esta opcionalmente sustituido por uno o mas radicales; X es CH2, CH(CH3), CH(CN), CO y CS, entre otros; y microesferas de moxidectina, los cuales se suspenden en un vehiculo acuoso que comprende uno o mas agentes de suspension, agentes humectantes y/o conservantes y agua; y un metodo para prevenir o tratar una infestacion de parasitos usando las mismas
PE2021001827A 2019-05-03 2020-05-01 Composiciones farmaceuticas inyectables y usos de las mismas PE20220173A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962842709P 2019-05-03 2019-05-03
PCT/EP2020/062181 WO2020225143A1 (en) 2019-05-03 2020-05-01 Injectable pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
PE20220173A1 true PE20220173A1 (es) 2022-01-28

Family

ID=70482684

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001827A PE20220173A1 (es) 2019-05-03 2020-05-01 Composiciones farmaceuticas inyectables y usos de las mismas

Country Status (13)

Country Link
US (1) US20220296564A1 (es)
EP (1) EP3962448A1 (es)
JP (1) JP2022531590A (es)
KR (1) KR20220004158A (es)
CN (1) CN113784702A (es)
AU (1) AU2020268618A1 (es)
CA (1) CA3138263A1 (es)
CL (1) CL2021002865A1 (es)
CO (1) CO2021014266A2 (es)
IL (1) IL287628A (es)
MX (1) MX2021013429A (es)
PE (1) PE20220173A1 (es)
WO (1) WO2020225143A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3707128B1 (en) * 2017-11-07 2023-12-20 Intervet International B.V. Injectable isoxazoline pharmaceutical compositions and their use against parasite infestation
AU2020404003A1 (en) * 2019-12-16 2022-05-26 Intervet International B.V. Parasite control in ruminants
WO2022255463A1 (ja) * 2021-06-02 2022-12-08 日本農薬株式会社 ベンゾイミダゾール化合物又はその塩類及び該化合物を含有する犬糸状虫症防除剤並びにその使用方法
CN116236448A (zh) * 2023-03-07 2023-06-09 四川新益峰生物制药有限公司 一种高效的阿苯达唑伊维菌素预混剂分散体颗粒组方与生产工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US4916154A (en) 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
ES2086022T3 (es) 1991-07-23 1996-06-16 American Cyanamid Co Composiciones estables para administracion parenteral y su uso.
DE60133706T2 (de) 2000-10-10 2009-07-02 Wyeth Holdings Corp. Stabilisierte Arzneizusammensetzungen zur parenteralen Vearbreichung
WO2005085216A1 (ja) 2004-03-05 2005-09-15 Nissan Chemical Industries, Ltd. イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
NO2957284T3 (es) 2007-06-27 2018-06-16
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
WO2009063910A1 (ja) 2007-11-12 2009-05-22 Nissan Chemical Industries, Ltd. 光学活性イソキサゾリン化合物の触媒的不斉合成方法
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
CA2747060A1 (en) 2008-12-18 2010-07-15 Novartis Ag Isoxazolines derivatives and their use as pesticide
WO2010070068A2 (en) 2008-12-19 2010-06-24 Novartis Ag Organic compounds
JP5679102B2 (ja) 2009-08-03 2015-03-04 日産化学工業株式会社 ジヒドロイソキサゾール置換安息香酸化合物の光学活性体とジアステレオマー塩及びその製造方法
TWI487486B (zh) 2009-12-01 2015-06-11 Syngenta Participations Ag 以異唑啉衍生物為主之殺蟲化合物
AU2011236510A1 (en) 2010-04-08 2012-10-11 Zoetis Llc Substituted 3,5- di phenyl - isoxazoline derivatives as insecticides and acaricides
US10350196B2 (en) 2013-09-30 2019-07-16 Zoetis Services Llc Long-acting spiro-isoxazoline formulations
UY36570A (es) 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
SG11201708068PA (en) 2015-04-08 2017-10-30 Merial Inc Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
WO2018039508A1 (en) * 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments
WO2019012377A1 (en) 2017-07-10 2019-01-17 Basf Se MIXTURES COMPRISING AN INSECTICIDE AND A NITRIFICATION INHIBITOR SUCH AS 2- (3,4-DIMETHYL-1H-PYRAZOL-1-YL) SUCCINIC ACID (DMPSA) OR 3,4-DIMETHYL PYRAZOLIUM GLYCOLATE (DMPG)

Also Published As

Publication number Publication date
US20220296564A1 (en) 2022-09-22
MX2021013429A (es) 2021-12-10
EP3962448A1 (en) 2022-03-09
CO2021014266A2 (es) 2021-10-29
CL2021002865A1 (es) 2022-06-17
JP2022531590A (ja) 2022-07-07
CA3138263A1 (en) 2020-11-12
KR20220004158A (ko) 2022-01-11
WO2020225143A1 (en) 2020-11-12
AU2020268618A1 (en) 2021-11-04
IL287628A (en) 2021-12-01
CN113784702A (zh) 2021-12-10

Similar Documents

Publication Publication Date Title
PE20220173A1 (es) Composiciones farmaceuticas inyectables y usos de las mismas
AR044909A1 (es) Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR079648A1 (es) Inhibidores de la replicacion del virus de la hepatitis c
AR053228A1 (es) Derivados de azol en calidad de inibidores de lipasas y fosfolipasas
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
CO6190512A2 (es) Compuestos antagonistas del receptor de glucagon composiciones que contienen dichos compuestos y procedimientos de uso
AR048232A1 (es) Piperidinilcarbonil- pirrolidinas y su uso como agonistas de melanocortina cr4
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR047456A1 (es) Derivados de amidas, procesos para su preparacion y uso como insecticidas
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
AR075717A1 (es) Compuestos de 3- aril quinazolin -4- ona para combatir plagas de invertebrados
AR091786A1 (es) Inhibidores de la produccion de leucotrienos
AR048427A1 (es) Derivados de sulfonilpirroles con actividad inhibitoria de la histona deacetilasa, composiciones farmaceuticas que los contienen y el uso de las mismas para el tratamiento de enfermedades relacionadas.
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
AR048974A1 (es) Derivados sustituidos del dioxido de oxazol-benzoisotiazol y composiciones farmaceuticas.
AR087607A1 (es) Derivados de piridazinona
PE20221764A1 (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
AR111756A1 (es) 4-difluorometilbenzoilamidas de acción herbicida
AR095164A1 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica
CO2017008809A2 (es) Compuestos de benzoxaborol y uso de los mismos
AR048717A1 (es) Derivados de acido hexenoico, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas
AR046793A1 (es) Derivados de pirazol, antagonistas del receptor de la orexina